Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 08/06/2021
• Auteurs : Frédéric HilezianXavier MoissetClemence BoutiereAudrey RicoSarah DemortierePhilippe KerschenThomas SeneCaroline Bensa-KoscherClaire GiannesiniJean CapronArsène MékinianJean-Philippe CamdessanchéGéraldine AndrodiasRomain MarignierNicolas CollonguesOlivier CasezCatalina CoclituMathieu VaillantGuillaume MatheyJonathan CironJean PelletierBertrand Audoin
• Organismes : Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM] Centre de résonance magnétique biologique et médicale Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM] Médecine légale [Hôpital de la Timone - APHM] Centre de résonance magnétique biologique et médicale Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM] Centre de résonance magnétique biologique et médicale Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM] Service de neurologie [CHRU Nancy] Centre Hospitalier de Luxembourg [Luxembourg] CHU Rothschild [AP-HP] CHU Rothschild [AP-HP] CHU Saint-Antoine [AP-HP] CHU Saint-Antoine [AP-HP] CHU Saint-Antoine [AP-HP] Service de Neurologie [CHU de Saint-Étienne] Hospices Civils de Lyon Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Service de Neurologie [Strasbourg] Pôle Psychiatrie et Neurologie [Grenoble] Pôle Psychiatrie et Neurologie [Grenoble] Pôle Psychiatrie et Neurologie [Grenoble] Service de neurologie [CHRU Nancy] Neurologie générale et maladies inflammatoires du système nerveux [Toulouse] Centre de résonance magnétique biologique et médicale Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM] Centre de résonance magnétique biologique et médicale Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM]
• Publié dans Journal of Neurology, Neurosurgery and Psychiatry le 25/10/2020

---

Résumé : Objective To assess the efficacy of tumour necrosis factor-α (TNF-α) inhibitors used as steroid-sparing monotherapy in central nervous system (CNS) parenchymal sarcoidosis. Methods The French Multiple Sclerosis and Neuroinflammation Centers retrospectively identified patients with definite or probable CNS sarcoidosis treated with TNF-α inhibitors as steroid-sparing monotherapy. Only patients with CNS parenchymal involvement demonstrated by MRI and imaging follow-up were included. The primary outcome was the minimum dose of steroids reached that was not associated with clinical or imaging worsening during a minimum of 3 months after dosing change. Results Of the identified 38 patients with CNS sarcoidosis treated with TNF-α inhibitors, 23 fulfilled all criteria (13 females). Treatments were infliximab (n=22) or adalimumab (n=1) for a median (IQR) of 24 (17–40) months. At treatment initiation, the mean (SD) age was 41.5 (10.5) years and median (IQR) disease duration 22 (14–49.5) months. Overall, 60% of patients received other immunosuppressive agents before a TNF-α inhibitor. The mean (SD) minimum dose of steroids was 31.5 (33) mg before TNF-α inhibitor initiation and 6.5 (5.5) mg after (p=0.001). In all, 65% of patients achieved steroids dosing <6 mg/day; 61% showed clinical improvement, 30% stability and 9% disease worsening. Imaging revealed improvement in 74% of patients and stability in 26%. Conclusion TNF-α inhibitors can greatly reduce steroids dosing in patients with CNS parenchymal sarcoidosis, even refractory. Classification of evidence This study provides Class IV evidence that TNF-α inhibitor used as steroid-sparing monotherapy is effective for patients with CNS parenchymal sarcoidosis.

---

Fichiers liés : jnnp-2020-325665.full.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 03/06/2021
• Auteurs : Bernhard WernlyMichael BeilRaphael Romano BrunoStephan BinnebösselMalte KelmSviri SigalPeter Vernon van HeerdenAriane BoumendilAntonio ArtigasMaurizio CecconiBrian MarshRui MorenoSandra OeyenBernardo Bollen PintoWojciech SzczeklikSusannah LeaverSten Mikael WaltherJoerg SchefoldMichael JoannidisJesper FjølnerTilemachos ZafeiridisDylan de LangeBertrand GuidetHans FlaattenChristian JungJoannidis MichaelEller PhilippHelbok RaimundSchmutz RenéNollet JokeNeve Nikolaas DeBuysscher Pieter DeOeyen SandraSwinnen WalterMikačić MarijanaBastiansen AndersHusted AndreasDahle Bård E SCramer ChristineSølling ChristofferØrsnes DortheThomsen Jakob EdelbergPedersen Jonas JuulEnevoldsen Mathilde HummelmoseElkmann ThomasKubisz-Pudelko AgnieszkaPope AlanCollins AmyRaj Ashok SBoulanger CaroleFrey ChristianHart CiaranBolger ClareSpray DominicRandell GeorginaFilipe HelderWelters Ingeborg DGrecu IrinaEvans JaneCupitt JasonLord JennyHenning JeremyJones JoanneBall JonathanNorth JulieSalaunkey KiranGordoa Laura Ortiz-Ruiz DeBell LouiseBalasubramaniam MadhuVizcaychipi MarcelaFaulkner MariaMupudzi McdonaldLea-Hagerty MeganReay MichaelSpivey MichaelLove NicholasSpittle NickWhite NigelWilliams PatriciaMorgan PatrickWakefield PhillipaSavine RachelJacob ReniInnes RichardKapoor RitooHumphreys SallyRose SteveDowling SusanLeaver SusannahMane TarkeshwariLawton TomOgbeide VongayiKhaliq WaqasBaird YolandaRomen AntoineGalbois ArnaudGuidet BertrandVinsonneau ChristopheCharron CyrilThevenin DidierGuerot EmmanuelBesch GuillaumeSavary GuillaumeMentec HervéChagnon Jean-LucRigaud Jean-PhilippeQuenot Jean-PierreCastaneray JeremyRosman JérémyJulien MaizelTiercelet KellyVettoretti LucieHovaere Maud MoussetMessika MessikaDjibré MichelRolin NathalieBurtin PhilippeGarcon PierreNseir SaadValette XavierRabe ChristianBarth EberhardEbelt HenningFuest KristinaFranz MarcusHoracek MichaelSchuster MichaelMeybohm PatrickBruno Raphael RomanoAllgäuer SebastianDubler SimonSchaller Stefan JSchering StefanSteiner StephanDieck ThorbenRahmel TimGraf TobiasKoutsikou AnastasiaVakalos AristeidisRaitsiou BogdanFlioni Elli NikiNeou EvangeliaTsimpoukas FotiosPapathanakos GeorgiosMarinakis GiorgosKoutsodimitropoulos IoannisAikaterini KounougeriRovina NikolettaKourelea StyllianiPolychronis TasioudisZidianakis VasiiiosKonstantinia VryzaAidoni ZoiMarsh BrianMotherway CatherineRead ChrisMartin-Loeches IgnacioCracchiolo Andrea NevilleMorigi AristideCalamai ItaloBrusa StefaniaElhadi AhmedTarek AhmedKhaled AlaAhmed HazemBelkhair Wesal AliCornet Alexander DGommers DiederikLange Dylan DeBoven EvavanHaringman JasperHaas LennekeBerg Lettie van DenHoiting OscarJager Peter DeGerritsen Rik TDormans TomDieperink WillemBreidablik AlenaSlapgard AnitaRime Anne-KarinJannestad BenteSjøbøe BrittRice EvaAndersen Finn HStrietzel Hans FrankJensen Jan PeterLangørgen JørundTøien KirstiStrand KristianHahn MichaelKlepstad PålBiernacka AleksandraKluzik AnnaKudlinski BartoszMaciejewski DariuszStudzińska DorotaHymczak HubertStefaniak JanSolek-Pastuszka JoannaZorska JoannaCwyl KatarzynaKrzych Lukasz JZukowski MaciejLipińska-Gediga MałgorzataPietruszko MarekPiechota MariuszSerwa MartaCzuczwar MiroslawZiętkiewicz MirosławKozera NataliaNasiłowski PawełSendur PawełZatorski PawełGalkin PiotrGawda RyszardKościuczuk UrszulaCyrankiewicz WaldemarGola WojciechPinto Alexandre FernandesFernandes Ana MargaridaSantos Ana RitaSousa CristinaBarros InêsFerreira Isabel AmorimBlanco Jacobo BacarizaCarvalho João TelesMaia JoseCandeias NunoCatorze NunoBelskiy VladislavLores AfricaMira Angela PradoCilloniz CatiaPerez-Torres DavidMaseda EmilioRodriguez EnverProl-Silva EstefaniaEixarch GasparGomà GemmaAguilar GerardoVelasco Gonzalo NavarroJaimes MariánirazábalVillamayor Mercedes IbarzFernández Noemí LlamasCubero Patricia JimenoLópez-Cuenca SoniaTomasa TeresaSjöqvist AndersBrorsson CamillaSchiöler FredrikWestberg HenrikNauska JessicaSivik JoakimBerkius JohanThiringer Karin KleivenDegeer LinaWalther StenBoroli FilippoSchefold Joerg CHergafi LeilaEckert PhilippeYıldız IsmailYovenko IhorNalapko YuriyNalapko YuriyPugh Richard
• Organismes : Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires - UR UPJV 7517
• Publié dans BMJ Open le 26/10/2020

---

Résumé : Objectives In Europe, there is a distinction between two different healthcare organisation systems, the tax-based healthcare system (THS) and the social health insurance system (SHI). Our aim was to investigate whether the characteristics, treatment and mortality of older, critically ill patients in the intensive care unit (ICU) differed between THS and SHI. Setting ICUs in 16 European countries. Participants In total, 7817 critically ill older (≥80 years) patients were included in this study, 4941 in THS and 2876 in the SHI systems. Primary and secondary outcomes measures We chose generalised estimation equations with robust standard errors to produce population average adjusted OR (aOR). We adjusted for patient-specific variables, health economic data, including gross domestic product (GDP) and human development index (HDI), and treatment strategies. Results In SHI systems, there were higher rates of frail patients (Clinical Frailty Scale>4; 46% vs 41%; p<0.001), longer length of ICU stays (90±162 vs 72±134 hours; p<0.001) and increased levels of organ support. The ICU mortality (aOR 1.50, 95% CI 1.09 to 2.06; p=0.01) was consistently higher in the SHI; however, the 30-day mortality (aOR 0.89, 95% CI 0.66 to 1.21; p=0.47) was similar between THS and SHI. In a sensitivity analysis stratifying for the health economic data, the 30-day mortality was higher in SHI, in low GDP per capita (aOR 2.17, 95% CI 1.42 to 3.58) and low HDI (aOR 1.22, 95% CI 1.64 to 2.20) settings. Conclusions The 30-day mortality was similar in both systems. Patients in SHI were older, sicker and frailer at baseline, which could be interpreted as a sign for a more liberal admission policy in SHI. We believe that the observed trend towards ICU excess mortality in SHI results mainly from a more liberal admission policy and an increase in treatment limitations. Trial registration numbers NCT03134807 and NCT03370692 .

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/06/2021
• Auteurs : Jean-Claude ThouretPierre BoivinD. MiallierFranck DonnadieuJ.-P. DumoulinPhilippe Labazuy
• Organismes : Laboratoire Magmas et Volcans Laboratoire Magmas et Volcans Laboratoire de Physique de Clermont Laboratoire Magmas et Volcans Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Laboratoire Magmas et Volcans
• Publié dans Geomorphology le 25/10/2020

---

Résumé : Few studies have focused on the post-eruption evolution of maar craters and associated lake level changes, al-though breaching of the crater rim poses mass-flow andflood hazards long after the initial eruption. LakePavin is a maar lake in the French Massif central formed by an eruption c. 6700 years ago. The maar is perchedon the edge of a glacially-shaped valley and the rim overlooks the surrounding subdued landscape. The rim isbreached to the north by an overflow channel, and to the south the maar has cut into theflank of the Montchalscoria cone and lavaflows. Incision of the lake outlet led to the growth of an alluvial fan that pushed the CouzePavin River towards the north side of the Gelat valley.Two lake terraces within the crater are used to determine stages in the evolution of the lake. The highstand Stage1 terrace +18 m above the current lake level indicates that the post-eruption lake surface and volume was 15%and 38% larger than the present-day lake, respectively, prior to the 5-7th Century CE. The poorly preserved Stage2 bench, +4.35 m on the west side of the natural dam, indicates that incision paused between Stage 1 andachievement of present lake level (Stage 3) before the 18th Century. Four units of streamflow deposits(c. 0.087 km2in area and 0.14–0.18 km3in volume) that formed the fan at the mouth of the outlet in the Gelatvalley have been14C dated to between the 9th and 16th Century. From the fan sedimentology, we infer thatthe lake level dropped slowly between highstand Stages 1 and 2, when the outlet cut down through the rim sad-dle. The lake level drop accelerated between Stage 2 and Stage 3 before the 14th Century, inducing small debrisflows. The latter may have resulted from heavy rainstorms, but there is no evidence for catastrophic events. Step-wise downcutting of the north rim saddle was also governed by contrasted properties of the deposits forming thedam. The current lake level has been stable since at least the early 18th Century, but the long-term stability of thedam is at risk

---

Fichiers liés : thouret2021.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 01/06/2021
• Auteurs : Pierre TissierKarim HassanVincent ReboudRemi VelardPhilippe GrosseStephane BernabeJean CharbonnierYvain ThonnartAlexis FarcyFabienne PonthenierBenoit CharbonnierJean-Emmanuel Broquin
• Organismes : STMicroelectronics [Crolles] Département Composants Silicium Institut de Microélectronique, Electromagnétisme et Photonique - Laboratoire d'Hyperfréquences et Caractérisation Département d'Optronique Département d'Optronique Département Composants Silicium Département d'Optronique Département d'Optronique Département Composants Silicium Laboratoire Fonctions Innovantes pour circuits Mixtes STMicroelectronics [Crolles] Département Composants Silicium Département d'Optronique Institut de Microélectronique, Electromagnétisme et Photonique - Laboratoire d'Hyperfréquences et Caractérisation

---

Résumé : Silicon ring resonators on SOI substrates are well known and widely studied. They are commonly used in datacom and high-performance computing for wavelength multiplexing and spectral filters. They can be tuned to the desired frequency with resistive heaters, which is the primary power budget of the device. In this work, the impact of backside cavities etched in the bulk silicon of SOI substrates below ring resonators is studied. Simulations show that those backside cavities improve significantly heat confinement and minimizes heat losses usually due to conduction in the Si substrate. Backside cavities have been successfully etched in the bulk of the SOI substrate to improve heat trapping within the silicon rings. The etching process is compatible with the standard silicon photonics interposer process flow. Power consumption studies have been performed with a reference ring resonator on SOI and ring resonators with different backside cavity diameters. These results will be discussed with respect to the backside cavity opening. A 72% power consumption reduction for a 10 µm diameter ring resonator on SOI has been achieved with a backside opening of 100 µm deep and 40µm diameter. The cavities opening did not impact the optical ring performances.

---

Fichiers liés : Backside_cavities_for_thermal_tuning_optimization_of_silicon_ring_resonators.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/06/2021
• Auteurs : Blandine TramuntSarra SmatiSandrine CoudolMatthieu WargnyMatthieu PichelinBéatrice GuyomarchAbdallah Al-SalamehCoralie AmadouSara BarraudÉdith BigotLyse BordierSophie BorotMuriel BourgeonOlivier BourronSybil CharrièreNicolas ChevalierEmmanuel CossonBruno FèveAnna Flaus-FurmaniukPierre FontaineAmandine GaliootCéline Gonfroy-LeymarieBruno GuerciSandrine LablancheJean-Daniel LalauEtienne LargerAdele LasbleizBruno LaviolleMichel MarreMarion MunchLouis PotierGaetan PrevostEric RenardYves ReznikDominique Seret-BeguePaul SibiliaPhilippe ThuillierBruno VergesJean-Francois GautierSamy HadjadjBertrand CariouFranck Mauvais-JarvisPierre Gourdy
• Organismes : Institut des Maladies Métaboliques et Cardiovasculaires ITX - unité de recherche de l'institut du thorax Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Nantes = Nantes University Hospital CHU Amiens-Picardie Périnatalité et Risques Toxiques - UMR INERIS_I 1 UPJV Centre Hospitalier Sud Francilien Hôpital universitaire Robert Debré [Reims] Centre de Recherche en Sciences et Technologies de l'Information et de la Communication - EA 3804 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Hôpital d'Instruction des Armées Begin [Saint-Mandé, France] Service de Diabétologie - Endocrinologie [CHRU Besançon] AP-HP - Hôpital Antoine Béclère [Clamart] Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] CHU Pitié-Salpêtrière [AP-HP] Centre de Recherche des Cordeliers Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] Hôpital Louis Pradel [CHU - HCL] Cardiovasculaire, métabolisme, diabétologie et nutrition Centre Hospitalier Universitaire de Nice Hôpital Jean Verdier [AP-HP] Centre for Research in Epidemiology and Statistics | Centre de Recherche Épidémiologie et Statistiques CHU Saint-Antoine [AP-HP] Centre hospitalier Félix-Guyon [Saint-Denis, La Réunion] Centre Hospitalier Régional Universitaire [CHU Lille] Hôpital Claude Huriez [Lille] Centre Hospitalier Universitaire de Bordeaux Centre Hospitalier René Dubos [Pontoise] Centre Hospitalier Régional Universitaire de Nancy Centre Hospitalier Universitaire [CHU Grenoble] CHU Amiens-Picardie AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris] Assistance Publique - Hôpitaux de Marseille Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Hôpital Ambroise Paré [AP-HP] Centre Hospitalier Universitaire [Strasbourg] AP-HP - Hôpital Bichat - Claude Bernard [Paris] Différenciation et communication neuronale et neuroendocrine Service d'endocrinologie, diabétologie et maladies métaboliques [Rouen] Institut de Génomique Fonctionnelle Centre Hospitalier Régional Universitaire [Montpellier] CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Centre Hospitalier de Gonesse Centre Hospitalier Universitaire d'Angers Groupe d'Etude de la Thrombose de Bretagne Occidentale CHU Dijon Service de Diabétologie et Endocrinologie Centre de Recherche des Cordeliers Centre d’Investigation Clinique de Nantes ITX - unité de recherche de l'institut du thorax Tulane University Centre Hospitalier Universitaire de Toulouse
• Publié dans European Journal of Endocrinology le 22/10/2020

---

Résumé : Objective - Male sex is one of the determinants of severe coronavirus diseas-e-2019 (COVID-19). We aimed to characterize sex differences in severe outcomes in adults with diabetes hospitalized for COVID-19. Methods - We performed a sex-stratified analysis of clinical and biological features and outcomes (i.e. invasive mechanical ventilation (IMV), death, intensive care unit (ICU) admission and home discharge at day 7 (D7) or day 28 (D28)) in 2380 patients with diabetes hospitalized for COVID-19 and included in the nationwide CORONADO observational study (NCT04324736). Results - The study population was predominantly male (63.5%). After multiple adjustments, female sex was negatively associated with the primary outcome (IMV and/or death, OR: 0.66 (0.49-0.88)), death (OR: 0.49 (0.30-0.79)) and ICU admission (OR: 0.57 (0.43-0.77)) at D7 but only with ICU admission (OR: 0.58 (0.43-0.77)) at D28. Older age and a history of microvascular complications were predictors of death at D28 in both sexes, while chronic obstructive pulmonary disease (COPD) was predictive of death in women only. At admission, C-reactive protein (CRP), aspartate amino transferase (AST) and estimated glomerular filtration rate (eGFR), according to the CKD-EPI formula predicted death in both sexes. Lymphocytopenia was an independent predictor of death in women only, while thrombocytopenia and elevated plasma glucose concentration were predictors of death in men only. Conclusions - In patients with diabetes admitted for COVID-19, female sex was associated with lower incidence of early severe outcomes, but did not influence the overall in-hospital mortality, suggesting that diabetes mitigates the female protection from COVID-19 severity. Sex-associated biological determinants may be useful to optimize COVID-19 prevention and management in women and men.

---

Fichiers liés : Tramunt_et al_2021_Sex disparities in COVID-19 outcomes_accepted.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/06/2021
• Auteurs : Eric VandermolenPhilippe FerrandisFrédéric AllibertMassinissa NabetMartin RackJean-Pierre RaskinM. Cassé
• Organismes : Commissariat à l'énergie atomique et aux énergies alternatives - Laboratoire d'Electronique et de Technologie de l'Information SOITEC Semi-conducteurs à large bande interdite SOITEC Institute of Information and Communication Technologies, Electronics and Applied Mathematics Institute of Information and Communication Technologies, Electronics and Applied Mathematics Institute of Information and Communication Technologies, Electronics and Applied Mathematics Commissariat à l'énergie atomique et aux énergies alternatives - Laboratoire d'Electronique et de Technologie de l'Information
• Publié dans Journal of Applied Physics le 02/11/2020

---

Résumé : In this study, high-resistivity gold-implanted silicon substrates developed for radio frequency (RF) applications were characterized. By varying PICTS (Photo-Induced Current Transient Spectroscopy) measurement conditions such as the illumination wavelength, we identified the signature and the nature of four dominant traps. Two were electron traps and the others were hole traps. All of the related defects involved gold atoms. RF simulations of coplanar waveguide transmission lines integrated on these substrates were carried out, based on the trap properties extracted from PICTS results. A good agreement between RF experimental data and simulations was achieved by tuning the trap concentrations. Finally, the gold density extracted from the fit was successfully compared with the secondary ion mass spectrometry profile and an explanation of the role of the traps in RF behavior of the substrate was given

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/06/2021
• Auteurs : Rémi LetestuAbdelmalek DahmaniMarouane BoubayaLucile BaseggioLydia CamposBernard ChatelainAgathe DebliquisBernard DrénouMarie-Christine JacobEric LegacMagali Le Garff-TavernierAnne-Catherine LhoumeauClaire QuineyNelly RobillardMichel TicchioniCarmen AaneiSandrine KatsahianRoselyne DelepineSandrine VaudauxValérie RouilléMarie-Christine BénéCaroline DartigeasEric van den NesteStéphane LeprêtrePierre FeugierGuillaume CartronVéronique LeblondVincent LévyFlorence CymbalistaSylvie CailleresGandhi DamajBruno RoyerMartine GardembasMamoun DibMatgorzata Truchan-GraczykMathilde Hunault-BergerCharles FoussardBernadette CorrontAnne ParryFrédérique Orsini-PiocelleSébastien TrouillierBohiane SlamaGérard LepeuHacene ZerazhiOlivier BoulatAhmed AzzedineCarla AraujoAnne BanosFrédéric BauduerJean-Luc DutelKamel GhomariEric DeconinckAnnie BrionJacqueline VuillierAlain SaadAbderrazak El YamaniPhilippe RodonPierre SoubeyranGabriel EtienneMarie-Sarah DilhuydyKrimo BouabdallahThibaut LeguayBachra ChouffiBertrand PolletAbdallah MaakarounGaëlle GuillermChristian BerthouNathalie CheronMarc AndréJean Pierre VilqueChristophe FruchartLaurent VoillatGian Matteo PicaSélim CormJean-Michel MicléaBertrand SouleauCécile Molucon-ChabrotBenoit de RenzisOlivier TournilhacJacques-Olivier BayCarine ChaleteixRomain GuiezeJoel FleuryCristina PrecupanuSelwa BouledrouaStéphanie HaiatCharlotte PetitdidierJehan DupuisKarim BelhadjOlivier CasasnovasJean-Noel BastieEmmanuelle FerrantDany GholamLysiane MolinaFrédéric GarbanMourad TiabHervé MaisonneuveBruno VillemagneDominique JacomyCaroline BessonGérard TertianKamel LaribiPierre MorelBruno CazinStéphane MoreauLiliane ReminierasMarie-José RappPhilippe MoreauCatherine SebbanAnne-Sophie MichalletGilles André SallesFlorence BroussaisThérèse Aurran-SchleinitzDiane CosoWajed AbarahClaire KulekciVéronique DorvauxPhilippe CarassouIsabelle GuibaudBernard ChristianCarlos GrauxJean-François RossiPhilippe QuittetAlain DuboisJean-Claude EisenmannNadine MorineauBéatrice MahéJean-Michel KarsentiEric JourdanÉric LegouffeMagda Alexis-VigierJean-Michel BouletMalek AoudjhaneCatherine ThiéblemontAnna Lisa AndreoliFrançois DreyfusSylvain ChoquetKarim MaloumHélène Merle-BéralAnne VekhoffDidier DecaudinPhilippe BraultRichard DelarueMaud JanvierCarole SoussainXavier VallantinLaurence SanhesBrigitte DreyfusCécile TomowiakRiad BenramdaneHugo GonzalezAnne Blaise-BrennaBrigitte KolbAlain DelmerCharles DauriacRoch HouotMartine Escoffre-BarbeThierry LamySophie de GuibertMarc BernardBernard GrosboisOana BreharPatrick MoriceDenis GuyotatJérome JaubertChristelle PortoisLuc-Matthieu ForneckerRaoul HerbrechtKarin BilgerShanti AmeLoic YsebaertPascal GodmerHenry Jardel
• Organismes : Hôpital Avicenne [AP-HP] Signalisation, Microenvironnement et Hémopathies Lymphoïdes B Hôpital Avicenne [AP-HP] Hôpital Avicenne [AP-HP] Centre Hospitalier Lyon Sud [CHU - HCL] Immuno-Biologie des Lymphomes [CIRI] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] CHU UCL Namur Groupe hospitalier de la région de Mulhouse Sud-Alsace Groupe hospitalier de la région de Mulhouse Sud-Alsace Centre Hospitalier Universitaire [CHU Grenoble] Centre Hospitalier Regional d'Orléans CHU Pitié-Salpêtrière [AP-HP] Institut Paoli-Calmettes CHU Pitié-Salpêtrière [AP-HP] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Nice Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Hopital Saint-Louis [AP-HP] Centre Hospitalier Régional Universitaire de Tours Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Régional Universitaire de Tours Université Catholique de Louvain = Catholic University of Louvain Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Centre Hospitalier Régional Universitaire de Nancy Centre Hospitalier Régional Universitaire [Montpellier] Université de Montpellier CHU Pitié-Salpêtrière [AP-HP] Hôpital Avicenne [AP-HP] Hôpital Avicenne [AP-HP] Lymphocytes B, Autoimmunité et Immunothérapies
• Publié dans Leukemia le 25/10/2020

---

Résumé : Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10-5) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow (N = 339), after fludarabine, cyclophosphamide, and rituximab (FCR)-based chemoimmunotherapy in a homogeneous population with long follow-up (median 49.5 months). Addition of low-level positive MRD < 0.01% to MRD ≥ 0.01% increased the proportion of cases with positive MRD in blood by 39% and in bone marrow by 27%. Compared to low-level positive MRD < 0.01%, undetectable MRD was associated with significantly longer progression-free survival (PFS) when using blood (72.2 versus 42.7 months; hazard ratio 0.40, p = 0.0003), but not when using bone marrow. Upon further stratification, positive blood MRD at any level, compared to undetectable blood MRD, was associated with shorter PFS irrespective of clinical complete or partial remission, and a lower 5-year PFS rate irrespective of IGHV-mutated or -unmutated status (all p < 0.05). In conclusion, high-sensitivity (0.0007%) MRD assessment in blood yielded additional prognostic information beyond the current standard sensitivity (0.01%). Our approach provides a model for future determination of the optimal MRD investigative strategy for any regimen.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/06/2021
• Auteurs : Jean-Guillaume LetarouillyBenoît FlachaireCéline LabadieMaéva KyhengNicolas CohenJérémie SellamP. RichettePhilippe DieudePascal ClaudepierreBruno FautrelEric HouvenagelChi Duc NguyenMarie-Hélène GuyotNicolas SegaudLaurent MarguerieXavier DeprezJean-Hugues SalmonGuy BaudensCorinne Miceli-RichardElisabeth Solau-GervaisIsabelle Chary-ValckenaerePierre LafforguePeggy PhilippeDamien LoeuilleChristophe RichezFlorence TubachThao PhamRené-Marc Flipo
• Organismes : Université de Lille Centre Hospitalier Régional Universitaire [CHU Lille] Aix Marseille Université Université de Bordeaux Evaluation des technologies de santé et des pratiques médicales - ULR 2694 Aix Marseille Université Centre de Recherche Saint-Antoine Biologie de l'Os et du Cartilage : Régulations et Ciblages Thérapeutiques Physiopathologie et Epidémiologie des Maladies Respiratoires Epidemiology in Dermatology and Evaluation in Therapeutics Sorbonne Université Institut Catholique de Lille Université de Reims Champagne-Ardenne Université Paris Cité Université de Poitiers = University of Poitiers Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Ingénierie Moléculaire et Physiopathologie Articulaire Service de Rhumatologie [CHRU Nancy] Institut des Sciences du Mouvement Etienne Jules Marey Centre Hospitalier Régional Universitaire [CHU Lille] Université de Poitiers = University of Poitiers Université de Bordeaux Institut Pierre Louis d'Epidémiologie et de Santé Publique Aix Marseille Université Université de Lille Centre Hospitalier Régional Universitaire [CHU Lille]
• Publié dans Rheumatology le 29/10/2020

---

Résumé : Objectives: To evaluate the characteristics of patients (pts) with PsA treated by ustekinumab (UST) or secukinumab (SEK) and to compare real-world persistence of UST and SEK in PsA.Methods: In this retrospective, national, multicentre cohort study, pts with PsA (CASPAR criteria or diagnosis confirmed by the rheumatologist) initiating UST or SEK with a follow-up ≥6 months were included from January 2011 to April 2019. The persistence between SEK and UST was assessed after considering the potential confounding factors by using pre-specified propensity-score methods. Causes of discontinuation and tolerance were also collected.Results: A total of 406 pts were included: 245 with UST and 161 with SEK. The persistence rate was lower in the UST group compared with the SEK group [median persistence 9.4 vs 14.7 months; 26.4% vs 38.0% at 2 years; weighted hazard ratio (HR) = 1.42; 95% CI: 1.07, 1.92; P =0.015]. In subgroup analysis, the persistence rate of SEK associated with MTX was significantly higher than that of UST associated with MTX: HR = 2.20; 95% CI: 1.30, 3.51; P =0.001, in contrast to SEK vs UST monotherapy: HR = 1.06; 95% CI: 0.74, 1.53; P =0.75. Discontinuation due to inefficacy was reported in 91.7% (SEK) and 82.4% (UST) of pts. Discontinuation due to an adverse event was reported in 12.2% (SEK) and 7.7% (UST) of pts.Conclusion: In this first study comparing UST and SEK, the persistence of SEK was higher than that of UST in PsA. In subgroup analysis, this difference was only found in association with MTX.

---

Fichiers liés : article 15_hal.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/06/2021
• Auteurs : Anaïs MennecierChipepo KankasaPaulin FaoJean-Pierre MolesSabrina Eymard-DuvernayMwiya MwiyaSamiratou OuedraogoCatherine Chunda-LiyokaLeticia SakanaDavid RutagweraSouleymane TassembedoMaria Melany Wilfred-TongaBeatriz MosqueiraThorkild TylleskärNicolas NagotPhilippe Van De Perre
• Organismes : Centre Hospitalier Régional Universitaire [Montpellier] Pathogenesis and Control of Chronic and Emerging Infections University of Zambia [Lusaka] Centre Muraz [Bobo-Dioulasso, Burkina Faso] Centre Hospitalier Régional Universitaire [Montpellier] Pathogenesis and Control of Chronic and Emerging Infections Centre Hospitalier Régional Universitaire [Montpellier] Pathogenesis and Control of Chronic and Emerging Infections University of Zambia [Lusaka] Centre Muraz [Bobo-Dioulasso, Burkina Faso] University of Zambia [Lusaka] Centre Muraz [Bobo-Dioulasso, Burkina Faso] University of Zambia [Lusaka] Centre Muraz [Bobo-Dioulasso, Burkina Faso] University of Zambia [Lusaka] Centre Hospitalier Régional Universitaire [Montpellier] Pathogenesis and Control of Chronic and Emerging Infections University of Bergen Centre Hospitalier Régional Universitaire [Montpellier] Pathogenesis and Control of Chronic and Emerging Infections Centre Hospitalier Régional Universitaire [Montpellier] Pathogenesis and Control of Chronic and Emerging Infections
• Publié dans Contemporary Clinical Trials le 31/10/2020

---

Résumé : Post-natal HIV infection through breastfeeding remains a challenge in many low and middle-income countries, particularly due to non-availability of alternative infant feeding options and the suboptimal Prevention of Mother to Child Transmission of HIV-1 (PMTCT) cascade implementation and monitoring. The PROMISE-EPI study aims to address the latter by identifying HIV infected mothers during an almost never-missed visit for their infant, the second extended program on immunization visit at 6-8 weeks of age (EPI-2). The study is divided into 3 components inclusive of an open-label randomized controlled trial aiming to assess the efficacy of a responsive preventive intervention compared to routine intervention based on the national PMTCT guidelines for HIV-1 uninfected exposed breastfeeding infants. The preventive intervention includes: a) Point of care testing for early infant HIV diagnosis and maternal viral load; b) infant, single-drug Pre-Exposure Prophylaxis (PrEP) (lamivudine) if mothers are virally unsuppressed. The primary outcome is HIV-transmission rate from EPI-2 to 12 months. The study targets to screen 37,000 mother/infant pairs in Zambia and Burkina Faso to identify 2000 mother/infant pairs for the clinical trial. The study design and challenges faced during study implementation are described, including the COVID-19 pandemic and the amended HIV guidelines in Zambia in 2020 (triple-drug PrEP in HIV exposed infants guided by quarterly maternal viral load). The changes in the Zambian guidelines raised several questions including the equipoise of PrEP options, the standard of care-triple-drug (control arm in Zambia) versus the study-single-drug (intervention arm). Trial registration number (www.clinicaltrials.gov): NCT03869944. Submission category: Study Design, Statistical Design, Study Protocols.

---

Fichiers liés : S1551714421001385.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/06/2021
• Auteurs : Maïté LewinChristophe DesterkeCatherine GuettierPierre-Jean ValetteHélène AgostiniStéphanie Franchi-AbellaLionel ArrivéAnita PaisantPhilippe PetitOlivier SoubraneDidier SamuelRené AdamValérie VilgrainBenoît GallixMarie-Pierre Vullierme
• Organismes : Centre Hépato-Biliaire [Hôpital Paul Brousse] Modèles de Cellules Souches Malignes et Thérapeutiques Hôpital Paul Brousse Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Centre Hospitalier Lyon Sud [CHU - HCL] Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] LaBoratoire d'Imagerie biOmédicale MultimodAle Paris-Saclay Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] CHU Saint-Antoine [AP-HP] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] LAB PSA Renault Hôpital Beaujon [AP-HP] Université Paris Diderot - Paris 7 Centre Hépato-Biliaire [Hôpital Paul Brousse] Centre Hépato-Biliaire [Hôpital Paul Brousse] Centre de recherche sur l'Inflammation Hôpital Beaujon [AP-HP] Hôpital Beaujon [AP-HP] UFR Médecine [Santé] - Université Paris Cité
• Publié dans American Journal of Roentgenology le 26/10/2020

---

Résumé : OBJECTIVE. The purpose of this multicenter retrospective study was to assess the MRCP features of Caroli disease (CD). MATERIALS AND METHODS. Sixty-six patients were identified from 2000 to 2019. The inclusion criteria were diagnosis of diffuse or localized CD mentioned in an imaging report, presence of intrahepatic bile duct (IHBD) dilatation, and having undergone an MRCP examination. The exclusion criteria included presence of obstructive proximal biliary stricture and having undergone hepatobiliary surgery other than cholecystectomy. Histopathology records were available for 53 of the 66 (80%) patients. Diffuse and localized diseases were compared by chi-square and t tests and Kaplan-Meier model. RESULTS. Forty-five patients had diffuse bilobar CD ((five pediatric patients [three girls and two boys] with a mean [± SD] age of 8 ± 5 years [range, 1–15 years] and 40 adult patients [26 men and 14 women] with a mean age of 35 ± 11 years [range, 20–62 years]) and 21 patients had localized disease (12 men and 9 women; mean age, 54 ± 14 years). Congenital hepatic fibrosis was found only in patients with diffuse CD (35/45 [78%]), as was a “central dot” sign (15/35 [43%]). IHBD dilatation with both saccular and fusiform features was found in 43 (96%) and the peripheral “funnel-shaped” sign in 41 (91%) of the 45 patients with diffuse CD but in none of the patients with localized disease (p < .001). Intrahepatic biliary calculi were found in all patients with localized disease but in only 16 of the 45 (36%) patients with diffuse CD (p < .001). Left liver atrophy was found in 18 of the 21 (86%) patients with localized disease and in none of the patients with diffuse CD (p < .001). The overall survival rate among patients with diffuse CD was significantly lower than that among patients with localized disease (p = .03). CONCLUSION. Diffuse IHBD dilatation with both saccular and fusiform features associated with the peripheral funnel-shaped sign can be used for the diagnosis of CD on MRCP. Localized IHBD dilatation seems to be mainly related to primary intrahepatic lithiasis.

---

Source